Myomo Follows “Path of Perseverance,” Rolls Out Next-Gen Robotic Arm System for Stroke Patients

(for motivation) and a “connected health” Web portal that a physical therapist or family member can log into to check up on the patient’s progress.

Some hopeful signs: Myomo has new partnerships with hospitals and clinicians around Boston, Chicago, and Southern California, as well as the University of Cincinnati’s Drake Center, University of Ulster (for game mechanics), and, as of last month, the Cleveland Clinic.

Marketing to patients and doctors is still a key challenge, of course. But Myomo’s portable device sells for $5,250, instead of around $80,000 for a stationary rehabilitation machine you might find in a hospital. The U.S. market for the device is a decent size—about 4 million patients and growing. There are some 400,000 new stroke patients a year in the U.S. who could benefit from it (out of a total annual pool of 750,000), Lewis says. But to reach them, the company needs to get two messages out to the public, according to Kelly. One is that some stroke patients can and do improve their arm function with therapy and practice (apparently this is not widely known). The second is that “personal robotics” technology can help patients get there.

Myomo has been backed by angel investors to date (less than $5 million in financing as of April 2009). Kelly wouldn’t rule out raising a venture capital round, but the firm has no stated plans to do so. The company is branching out to customers beyond stroke patients, including people with brain or spinal cord injuries and other forms of muscle weakness. If Myomo is successful with its elbow device, Kelly says, it could also move into assisting other joints in the body. (You can read about powered “exoskeleton” projects here, which have a similar concept but are for different applications, mostly military.)

Kelly talked a little about his vision for a “personal mobility system” that, in principle, could encompass something like a full-body suit for roughly the price of a car. But that’s for even further down the road. For now, Myomo is focusing on a specific joint (the elbow) and a specific pool of patients (those who have suffered strokes or other neurological injuries). And it wants to sell a lot of devices, fast.

“We can help a lot of people with this,” Kelly says. “Just being able to move is so elemental.”

Author: Gregory T. Huang

Greg is a veteran journalist who has covered a wide range of science, technology, and business. As former editor in chief, he overaw daily news, features, and events across Xconomy's national network. Before joining Xconomy, he was a features editor at New Scientist magazine, where he edited and wrote articles on physics, technology, and neuroscience. Previously he was senior writer at Technology Review, where he reported on emerging technologies, R&D, and advances in computing, robotics, and applied physics. His writing has also appeared in Wired, Nature, and The Atlantic Monthly’s website. He was named a New York Times professional fellow in 2003. Greg is the co-author of Guanxi (Simon & Schuster, 2006), about Microsoft in China and the global competition for talent and technology. Before becoming a journalist, he did research at MIT’s Artificial Intelligence Lab. He has published 20 papers in scientific journals and conferences and spoken on innovation at Adobe, Amazon, eBay, Google, HP, Microsoft, Yahoo, and other organizations. He has a Master’s and Ph.D. in electrical engineering and computer science from MIT, and a B.S. in electrical engineering from the University of Illinois, Urbana-Champaign.